Which of the following describes the adverse drug reactions of eptinezumab (Vyepti)?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Multiple Choice

Which of the following describes the adverse drug reactions of eptinezumab (Vyepti)?

Eptinezumab is a monoclonal antibody against CGRP given by IV infusion for migraine prevention. The adverse event profile that best matches its typical and clinically important reactions includes nasopharyngitis and hypersensitivity. Nasopharyngitis reflects common, mild infection-like symptoms seen with many biologics, while hypersensitivity covers allergic or infusion-related reactions that can occur with monoclonal antibodies. Other symptoms like dizziness or nausea can occur with various therapies, but they are not the characteristic ADRs emphasized for this drug, and injection site reactions are more relevant to subcutaneous CGRP inhibitors rather than an IV infusion. Therefore, nasopharyngitis together with hypersensitivity best describes the adverse drug reactions of eptinezumab.

Eptinezumab is a monoclonal antibody against CGRP given by IV infusion for migraine prevention. The adverse event profile that best matches its typical and clinically important reactions includes nasopharyngitis and hypersensitivity. Nasopharyngitis reflects common, mild infection-like symptoms seen with many biologics, while hypersensitivity covers allergic or infusion-related reactions that can occur with monoclonal antibodies. Other symptoms like dizziness or nausea can occur with various therapies, but they are not the characteristic ADRs emphasized for this drug, and injection site reactions are more relevant to subcutaneous CGRP inhibitors rather than an IV infusion. Therefore, nasopharyngitis together with hypersensitivity best describes the adverse drug reactions of eptinezumab.

More practice questions